4,760 results match your criteria American journal of clinical oncology[Journal]


ACR-ASTRO Practice Parameter for Image-guided Radiation Therapy (IGRT).

Am J Clin Oncol 2020 May 22. Epub 2020 May 22.

American College of Radiology, Reston, VA.

Aim/objectives/background: The American College of Radiology (ACR) and the American Society for Radiation Oncology (ASTRO) have jointly developed the following practice parameter for image-guided radiation therapy (IGRT). IGRT is radiation therapy that employs imaging to maximize accuracy and precision throughout the entire process of treatment delivery with the goal of optimizing accuracy and reliability of radiation therapy to the target, while minimizing dose to normal tissues.

Methods: The ACR-ASTRO Practice Parameter for IGRT was revised according to the process described on the ACR website ("The Process for Developing ACR Practice Parameters and Technical Standards," www. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000697DOI Listing

ACR-ASTRO Practice Parameter for the Performance of Stereotactic Body Radiation Therapy.

Am J Clin Oncol 2020 May 12. Epub 2020 May 12.

Department of Radiation Oncology, Dartmouth-Hitchcock Medical Center, Lebanon, NH.

Aim/objectives/background: To standardize the practice of stereotactic body radiation therapy (SBRT), the American College of Radiology (ACR) and the American Society for Radiation Oncology (ASTRO) cooperatively developed the practice parameter for SBRT. SBRT is a treatment technique that delivers radiation dose to a well-defined extracranial target in 5 fractions or less and usually employs a higher dose per fraction than used in conventional radiation.

Methods: The ACR-ASTRO Practice Parameter for the Performance of Stereotactic Body Radiation Therapy was revised according to the process described on the ACR website ("The Process for Developing ACR Practice Parameters and Technical Standards," www. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000706DOI Listing

Does the Interval Between Hysterectomy and Start of Adjuvant Radiation Treatment Influence Survival in Women With Endometrial Carcinoma?: A National Cancer Database analysis.

Am J Clin Oncol 2020 May 8. Epub 2020 May 8.

Departments of Radiation Oncology.

Objective: The objective of this study was to analyze the impact of the time interval (TI) between hysterectomy and initiation of adjuvant radiation treatment (ART) on overall survival (OS) among women with early stage endometrial carcinoma (EC) using the National Cancer Database (NCDB).

Materials And Methods: The NCDB was queried for women with the International Federation of Gynecology and Obstetrics (FIGO) stage I to II EC who underwent hysterectomy followed by ART. We examined the prognostic impact of TI on OS using the cutoff ≤8 or >8 weeks to initiate radiation treatment (RT). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000713DOI Listing

Eligibility Criteria and Endpoints in Metastatic Renal Cell Carcinoma Trials.

Am J Clin Oncol 2020 May 8. Epub 2020 May 8.

Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre.

Objectives: Treatments for metastatic renal cell carcinoma (mRCC) are often compared across trials, but trial eligibility criteria and endpoints differ. In an effort to better align trials, the Definition for the Assessment of Time to event Endpoints in CANcer trials (DATECAN) project published recommendations in 2015 to be used in mRCC clinical trial design. We analyzed mRCC trial criteria to determine if DATECAN's recommendations were followed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000705DOI Listing
May 2020
2.611 Impact Factor

"Was It Worth It?": A Pilot Study in Patient Perspectives on the Worthwhileness of Radiation Therapy.

Am J Clin Oncol 2020 May 1. Epub 2020 May 1.

Department of Radiation Medicine.

Objectives: Radiation therapy is a core oncologic treatment, but literature detailing patient satisfaction post-treatment is sparse. The authors conducted a pilot study to determine whether a simple survey would be feasible to administer and could elucidate factors predictive of satisfaction with radiotherapy.

Materials And Methods: Patients with cancer receiving radiotherapy in an academic radiation oncology department from 2014 to 2015 received a 4-item radiotherapy-focused version of the "Was It Worth It?" questionnaire (r-WIWI) on the last day of treatment and at the first follow-up. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000711DOI Listing

Analyzing the Time From Discovery to Definitive Surgical Therapy for Lung Cancer Based on Referral Patterns.

Am J Clin Oncol 2020 May 1. Epub 2020 May 1.

Department of Surgery, Division of Thoracic Surgery, The George Washington University Hospital, Washington, DC.

Objective: Surgery for early stage non-small cell lung cancer can be curative. A delay from diagnosis to surgery can lead to increased mortality. Our objective was to determine if referring patients to specialists before a thoracic surgeon caused a delay in definitive treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000710DOI Listing

Survival Benefit of Combination Chemotherapy in Elderly Patients With Metastatic Pancreatic Ductal Adenocarcinoma.

Am J Clin Oncol 2020 Apr 28. Epub 2020 Apr 28.

Division of Medical Oncology.

Objectives: Survival benefit of combination over single-agent chemotherapy for metastatic pancreatic ductal adenocarcinoma (PDAC) was demonstrated in younger patients in clinical trials. The authors aimed to evaluate whether this survival benefit of combination chemotherapy is present in elderly patients with metastatic PDAC.

Materials And Methods: The authors identified elderly patients (age 65 y or older) with stage IV PDAC and extracted available clinical information from a prospectively maintained institutional pancreatic cancer registry from 2007 to 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000708DOI Listing

The Population-based Impact of Adjuvant Chemotherapy on Outcomes in T2N0M0 Non-Small Cell Lung Cancer.

Am J Clin Oncol 2020 Apr 28. Epub 2020 Apr 28.

Department of Oncology, University of Calgary, Calgary, AB, Canada.

Objectives: The value of adjuvant chemotherapy in T2N0M0 non-small-cell lung cancer (NSCLC) is unclear. Some current guidelines suggest adjuvant chemotherapy be considered for patients with tumors ≥4 cm. Prior population-based evaluations lacked lung cancer-specific survival (LCSS) and health insurance status. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000694DOI Listing

Heterogenous Dose-escalated Prostate Stereotactic Body Radiation Therapy for All Risk Prostate Cancer: Quality of Life and Clinical Outcomes of an Institutional Pilot Study.

Am J Clin Oncol 2020 Apr 28. Epub 2020 Apr 28.

Department of Radiation Oncology, Taussig Cancer Institute.

Objectives: Previous prostate stereotactic body radiation therapy studies delivered uniform doses of 35 to 40 Gy/5 fx. Attempts at uniform dose escalation to 50 Gy caused high rates of gastrointestinal (GI) toxicity. We hypothesize that heterogeneous dose escalation to regions nonadjacent to sensitive structures (urethra, rectum, and bladder) is safe and efficacious. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000693DOI Listing

Capecitabine, Oxaliplatin, Irinotecan, and Bevacizumab Combination Followed by Pazopanib Plus Capecitabine Maintenance for High-Grade Gastrointestinal Neuroendocrine Carcinomas.

Am J Clin Oncol 2020 May;43(5):305-310

Unit of Clinical Pharmacology and Therapeutic Oncology, Department of Pharmacology, Medical School, National and Kapodistrian University of Athens.

Objectives: Gastrointestinal neuroendocrine carcinoma (NEC) is a lethal, uncommon, and understudied neoplasm. We present the efficacy and safety of first-line capecitabine (CP), oxaliplatin, irinotecan, and bevacizumab (CAPOXIRI-BEV) combination followed by pazopanib plus CP maintenance therapy in patients with advanced high-grade poorly differentiated gastrointestinal NEC.

Methods: This was a two-stage phase II study conducted at multiple institutions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000668DOI Listing
May 2020
2.611 Impact Factor

Stage-specific Conditional Survival Among Young (Age Below 50 y) Versus Older (Age 50 y and Above) Adults With Colorectal Cancer in the United States.

Am J Clin Oncol 2020 Apr 21. Epub 2020 Apr 21.

Departments of Radiation Oncology.

Background: Conditional survival (CS) is a relevant prognostic measure and may be particularly important for young adult patients with colorectal cancer (CRC), whose incidence is rising. We sought to compare CS among young versus older adults with CRC.

Methods: Patients diagnosed with CRC between 2004 and 2010 were identified from the Surveillance, Epidemiology, and End Results registry. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000698DOI Listing

Characterizing Urban-Rural Differences in Colon Cancer Outcomes: A Population-based Analysis Based on Travel Distance to Cancer Center.

Am J Clin Oncol 2020 Apr 21. Epub 2020 Apr 21.

Department of Oncology, Tom Baker Cancer Centre, University of Calgary, Calgary, AB, Canada.

Objective: We aimed to explore possible drivers for urban-rural disparities in colon cancer outcomes in a single-payer health care system where all patients had access to universal health care coverage.

Methods: Patients diagnosed with stage II/III colon cancer between 2004 and 2015 in Alberta, Canada were reviewed. On the basis of postal code, patients were categorized as living in urban, rural, or suburban areas based on travel distance to the cancer center. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000703DOI Listing
April 2020
2.611 Impact Factor

The Impact of the COVID-19 Pandemic on Cancer Patients.

Am J Clin Oncol 2020 06;43(6):452-455

Inpatient Pharmacist, The Specialty Hospital, Amman, Jordan.

In December 2019, a novel coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused an outbreak of coronavirus disease 2019 (COVID-19). Severe complications have been reported to occur in 33% of patients with COVID-19 and include acute respiratory distress syndrome, acute renal failure, acute respiratory injury, septic shock, and severe pneumonia. Currently, there is no specific treatment or approved vaccine against COVID-19 and many clinical trials are currently investigating potential medications to treat COVID-19. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000712DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7188063PMC

Tyrosine Kinase Inhibitors and the Relationship With Adherence, Costs, and Health Care Utilization in Commercially Insured Patients With Newly Diagnosed Chronic Myeloid Leukemia: A Retrospective Claims-Based Study.

Am J Clin Oncol 2020 Apr 16. Epub 2020 Apr 16.

The University of Texas Health Science Center at Houston School of Public Health (HLP, CEB, WC, TMK), Houston, TX.

Objective: To examine the association among tyrosine kinase inhibitor (TKI) out-of-pocket costs, adherence, and health care costs and utilization in a large group of commercially insured patients with chronic myeloid leukemia (CML).

Materials And Methods: Patients with CML aged 18 to 64 years were identified using IBM MarketScan Commercial Database between April 1, 2011 and December 31, 2014. Patients were required to be continuously enrolled 3 months before and 12 months after TKI (imatinib, dasatinib, or nilotinib) initiation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000700DOI Listing

A Prospective Study About Trastuzumab-induced Cardiotoxicity in HER2-positive Breast Cancer.

Am J Clin Oncol 2020 Apr 16. Epub 2020 Apr 16.

Departments of Medical Oncology.

Background: Trastuzumab improves therapeutic outcomes among patients with human epidermal growth factor receptor 2-positive breast cancer (BC). However, it is associated with a risk of treatment-induced cardiotoxicity. The aims of this study were to determine the frequency of trastuzumab-induced cardiotoxicity (TIC) in Tunisian patients, to study the effects of trastuzumab on cardiac biomarkers and echocardiographic parameters using the speckle tracking technique and to identify risk factors of occurrence of TIC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000699DOI Listing

A Phase 1 Study of SLC-0111, a Novel Inhibitor of Carbonic Anhydrase IX, in Patients With Advanced Solid Tumors.

Am J Clin Oncol 2020 Apr 2. Epub 2020 Apr 2.

BC Cancer.

Objectives: SLC-0111 is an ureido-substituted benzenesulfonamide small molecule inhibitor of carbonic anhydrase IX. The objectives of this first-in-human Phase 1 study were to determine the safety and tolerability of SLC-0111 in patients with advanced solid tumors and to establish the recommended Phase 2 dose for future clinical investigations.

Materials And Methods: Using a 3+3 design, dose escalation started at 500 mg oral daily dosing of SLC-0111 in cohort 1 and increased to 1000 and 2000 mg in cohorts 2 and 3. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000691DOI Listing

Combination Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis.

Am J Clin Oncol 2020 Apr 3. Epub 2020 Apr 3.

Department of Urology.

Introduction: Randomized clinical trials have shown combination therapy to be superior in progression-free survival (PFS) rates when compared with sunitinib alone. However, there have been no direct comparisons among the combination strategies making it unclear as to which may be the preferred option. We performed a network meta-analysis of the combination therapy (immune checkpoint inhibitor plus axitinib or bevacizumab) used in metastatic renal cell carcinoma (mRCC) and provided a rank order preference based on PFS, and adverse events (AEs). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000695DOI Listing

Racial and Geographic Disparities in Endocrine Therapy Adherence Among Younger Breast Cancer Survivors.

Am J Clin Oncol 2020 Apr 3. Epub 2020 Apr 3.

The Cancer Survivorship Center, College of Nursing.

Objectives: African American (AA) women with breast cancer (BrCA) have higher mortality than any other race. Differential mortality has been attributed to nonadherence to endocrine therapy (ET). ET can lower the risk of dying by one third; yet 50% to 75% of all women are nonadherent to ET. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000696DOI Listing

Neoadjuvant Phase II Trial of Chemoradiotherapy in Patients With Resectable and Borderline Resectable Pancreatic Cancer.

Am J Clin Oncol 2020 Jun;43(6):435-441

Division of Hematology and Medical Oncology.

Background: Pancreatic ductal adenocarcinoma is a largely incurable cancer. Surgical resection remains the only potential option for cure. Even in surgically resectable patients, only about 10% to 20% are long-term survivors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000688DOI Listing

Doxorubicin and Olaratumab Versus Doxorubicin, Ifosfamide, and Mesna for Treatment of Advanced Soft Tissue Sarcomas.

Am J Clin Oncol 2020 Jun;43(6):446-451

Division of Oncology, University of Washington.

Objective: We compared the outcomes in soft tissue sarcoma (STS) treated with olaratumab and doxorubicin (OD) versus doxorubicin, ifosfamide, and mesna (AIM) to assess whether OD could supersede AIM in STS therapy.

Methods: A single-institution, retrospective study of STS treated for advanced disease with OD or AIM in 2013 to 2017 was conducted. Demographic and clinical parameters were compared by Fisher's exact test. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000690DOI Listing

Brain Metastases From Gynecologic Malignancies: Prevalence and Management.

Am J Clin Oncol 2020 Jun;43(6):418-421

Division of Gynecologic Oncology.

Objective: The objective of this study was to investigate the prevalence, clinicopathologic characteristics, management, and outcomes of patients with brain metastasis (BM) from gynecologic malignancies in a large hospital-based database.

Materials And Methods: The National Cancer Database (NCDB) was accessed and patients with ovarian, uterine, or cervical cancer and BM were identified. We identified those who received radiation therapy (RT) as whole-brain radiation therapy (WBRT) or stereotactic radiosurgery (SRS). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000689DOI Listing

Patterns of Care for Stage II-III Rectosigmoid Cancers in the United States, 2004-2015.

Am J Clin Oncol 2020 May;43(5):311-318

Departments of Radiation Oncology.

Objectives: Although current guidelines continue to recommend trimodality therapy for stage II to III rectal cancers, a lower incidence of local recurrence has been observed in patients with upper rectal tumors, including those in the rectosigmoid. In practice, patients with upper rectal tumors may not be receiving all 3 modalities of therapy. Patterns of care for patients with rectosigmoid cancers have not previously been described. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000674DOI Listing

Risk of Recurrence and 10-Year Outcomes in Surgically Treated Nonmelanoma Skin Cancer in Cardiac and Liver Transplant Recipients.

Am J Clin Oncol 2020 May;43(5):366-370

Departments of Radiation Oncology.

Objectives: To report long-term outcomes of nonmelanoma skin cancer (NMSC) in immunosuppressed cardiac and liver transplant recipients (CLTR).

Materials And Methods: The authors reviewed CLTR at the Mayo Clinic in Arizona from 1986 to 2013. Patient and tumor characteristics were recorded. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000677DOI Listing
May 2020
2.611 Impact Factor

Diagnostic Test Accuracy of Glasgow Prognostic Score as a Prognostic Factor for Renal Cell Carcinoma: A Meta-Analysis.

Am J Clin Oncol 2020 Jun;43(6):393-398

Department of Urology, Bundang Jesaeng General Hospital, Seongnam, Korea.

Objective: The objective of this study was to perform a meta-analysis of the diagnostic test accuracy of Glasgow Prognostic Score (GPS) as a prognostic factor for renal cell carcinoma (RCC).

Materials And Methods: Studies were retrieved from PubMed, Cochrane, and Embase databases, and we performed comprehensive searches to identify studies that evaluated the prognostic impact of pretreatment GPS in RCC patients. We assessed sensitivity, specificity, summary receiver operating characteristic curve, and area under the curve (AUC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000687DOI Listing

Outcomes and the Role of Primary Histology Following LINAC-based Stereotactic Radiation for Sarcoma Brain Metastases.

Am J Clin Oncol 2020 May;43(5):356-361

Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL.

Objectives: The brain is a rare site for sarcoma metastases. Sarcoma's radioresistance also makes standard whole-brain radiotherapy less appealing. We hypothesize that stereotactic radiation techniques (stereotactic radiosurgery [SRS]/stereotactic fractionated radiotherapy [FSRT]) may provide effective local control. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000675DOI Listing
May 2020
2.611 Impact Factor

Six-Week Interval Between Preoperative Radiation and Surgery is Associated With Fewer Major Wound Complications in Soft Tissue Sarcoma.

Am J Clin Oncol 2020 Mar 25. Epub 2020 Mar 25.

Department of Orthopaedics, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH.

Objectives: A total of 30% to 40% of soft tissue sarcoma (STS) patients develop major wound complications (MWCs) after preoperative radiation (preRT). The optimal preRT-surgery interval and its association with MWCs is unknown. This study investigated whether a longer preRT-surgery interval is associated with fewer MWCs compared with historical controls. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000692DOI Listing

Association Between Metabolic Syndrome and Endometrial Cancer Survival in a SEER-Medicare Linked Database.

Am J Clin Oncol 2020 Jun;43(6):411-417

Departments of Radiation Oncology.

Background: Metabolic syndrome has previously been linked to increased risk of endometrial cancer. This study examines the association between metabolic syndrome and cancer-specific survival (CSS) in early stage and locoregionally advanced endometrial cancer.

Methods: The SEER-Medicare linked database was used to identify a cohort of patients with endometrial cancer between 1992 and 2011 who underwent hysterectomy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000686DOI Listing

Outcomes and Utilization of Adjuvant Chemotherapy for Stage II Colon Cancer in the Oxaliplatin Period: A SEER-Medicare Analysis.

Am J Clin Oncol 2020 Jun;43(6):428-434

Department of Medicine, Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA.

Purpose: Previous SEER (Surveillance, Epidemiology, and End Results)-Medicare analyses have shown no definitive survival benefit for adjuvant chemotherapy (AC) with fluoropyrimidines. Impact of oxaliplatin-containing regimens for elderly stage II patients in real-world setting is unknown. We explored the utilization and outcome of AC after the Food and Drug Administration (FDA) approval of oxaliplatin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000684DOI Listing

Twitter: A Platform for Dissemination and Discussion of Scientific Papers in Radiation Oncology.

Am J Clin Oncol 2020 Jun;43(6):442-445

Department of Radiation Oncology, Centre Hospitalier de l'Université de Montréal (CHUM).

Objective: The objective of this study was to examine the correlation between Twitter mentions and the number of academic citations of radiation oncology articles.

Materials And Methods: We reviewed all 178 clinical manuscripts of the 2 most important radiation oncology journals and "Brachytherapy," and all clinical manuscripts relating to radiation oncology from the top 10 impact factor oncology journals, published between January and February 2018. We collected the record of citations utilizing Scopus and Google Scholar platforms and the number of times an article was tweeted about using the "Altmetric Bookmarklet. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000685DOI Listing
June 2020
2.611 Impact Factor

Speak to Us of Love.

Am J Clin Oncol 2020 May;43(5):378-379

Harvard Medical School, Boston, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000683DOI Listing

Gemcitabine Plus Cisplatin Chemotherapy Prolongs the Survival in Advanced Hilar Cholangiocarcinoma: A Large Multicenter Study.

Am J Clin Oncol 2020 Jun;43(6):422-427

Department of Internal Medicine, Division of Gastroenterology, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam.

Objectives: Gemcitabine plus cisplatin (GC) is recommended as first-line treatment for advanced cholangiocarcinoma. We investigated the impact of GC in patients with unresectable hilar cholangiocarcinoma (HC) based on the time taken for effective biliary drainage (EBD).

Materials And Methods: We retrospectively enrolled 113 patients with unresectable HC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000682DOI Listing

Locoregional Therapy Protocols With and Without Radioembolization for Hepatocellular Carcinoma as Bridge to Liver Transplantation.

Am J Clin Oncol 2020 May;43(5):325-333

Department of Medicine, Division of Gastroenterology, Hepatology, and Nutrition.

Objective: The objective of this study was to compare posttransplant outcomes in patients undergoing bridging locoregional therapy (LRT) with Y-90 transarterial radioembolization (TARE) based protocol compared with transarterial chemoembolization based protocol for hepatocellular carcinoma (HCC) prior liver transplantation (LT).

Materials And Methods: Patients listed for LT with HCC within the Milan criteria at our center who had bridging LRT were treated according to transarterial chemoembolization (TACE) based protocol from May 2012 to April 2014 and a TARE based protocol from October 2014 to December 2017. Early posttransplant survival and tumor recurrence were compared between the groups. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000678DOI Listing

Modified-BEP Chemotherapy in Patients With Germ-Cell Tumors Treated at a Comprehensive Cancer Center.

Am J Clin Oncol 2020 Jun;43(6):381-387

Medical Division of Urogenital and Head and Neck Cancer.

Objectives: Bleomycin, etoposide, and cisplatin (BEP) is the most common and successful chemotherapy regimen for germ-cell tumor (GCT) patients, accompanied by a bleomycin-induced dose-dependent lung toxicity in certain patients. In an attempt to reduce bleomycin-toxicity, we developed a modified-BEP (mBEP) regimen.

Materials And Methods: Between August 2008 and February 2018, 182 unselected mainly testicular GCT patients (39 with adjuvant purpose and 143 with curative purpose) received a tri-weekly 5-day hospitalization schedule with bleomycin 15 U intravenous (IV) push on day 1 and 10 U IV continuous infusion over 12 hours on days 1 to 3, cisplatin 20 mg/m IV, and etoposide 100 mg/m IV on days 1 to 5. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000679DOI Listing

Prognostic Significance of Preoperative Prognostic Nutritional Index in Patients Undergoing Nephrectomy for Nonmetastatic Renal Cell Carcinoma.

Am J Clin Oncol 2020 Jun;43(6):388-392

Department of Urology, Bundang Jesaeng General Hospital, Seongnam, Korea.

Objective: The objective of this study was to assess the value of a preoperative Prognostic Nutritional Index (PNI) for predicting the survival of patients with nonmetastatic renal cell carcinoma (RCC) treated with partial or radical nephrectomy.

Materials And Methods: The medical records of 480 patients with RCC who underwent partial or radical nephrectomy at 2 institutions between June 1994 and July 2017 were retrospectively reviewed. After the exclusion of 21 patients with lymph node or distant metastasis, the data of 459 patients with nonmetastatic RCC were included. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000680DOI Listing

Refusal of Radiation Results in Inferior Survival in Endometrial Cancer.

Am J Clin Oncol 2020 Jun;43(6):399-410

Department of Radiation Oncology.

Objective: We sought to understand factors associated with refusal of adjuvant radiotherapy in endometrial cancer and its impact on outcomes.

Methods: Data from the National Cancer Database for patients who underwent surgery for nonmetastatic endometrial cancer between 2004 and 2015 were pooled. The Pearson χ test and multivariate logistic regression analyses were used to assess demographic, clinical, and treatment factors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000681DOI Listing

ACR-ASTRO Practice Parameter for the Performance of Proton Beam Radiation Therapy.

Am J Clin Oncol 2020 Mar;43(3):149-159

Dartmouth-Hitchcock Medical Center, Lebanon, NH.

Aim/objectives/background: The American College of Radiology (ACR) and the American Society for Radiation Oncology (ASTRO) have jointly developed the following practice parameter for proton beam radiation therapy. Proton radiotherapy is the application of a high-energy proton beam to a patient in a clinical setting with therapeutic intent. Proton radiotherapy may permit improved therapeutic ratios with lower doses to sensitive normal structures and greater dose to target tumor tissues. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000672DOI Listing
March 2020
2.611 Impact Factor

Determining Optimal Follow-up for Patients With Anal Cancer Following Chemoradiation.

Am J Clin Oncol 2020 May;43(5):319-324

Departments of Radiation Oncology.

Background: US health care is increasingly defined by over expenditure and inefficiency. Optimizing patient follow-up is critical, especially in cancers treated with high control rates. To optimize patient care, this study assessed time to disease recurrence or toxicity in patients with anal carcinoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000673DOI Listing

First-Line Treatment With Atezolizumab Plus Nab-Paclitaxel for Advanced Triple-Negative Breast Cancer: A Cost-Effectiveness Analysis.

Am J Clin Oncol 2020 May;43(5):340-348

Department of Pharmacy, The First Affiliated Hospital of Fujian Medical University, Fuzhou, Fujian Province.

Objective: The authors conducted a cost-effectiveness analysis incorporating recent phase III clinical trial (IMpassion130) data to evaluate the cost-effectiveness of atezolizumab in combination with nab-paclitaxel (AnP) against nab-paclitaxel alone as the first-line treatment for advanced triple-negative breast cancer in developed and developing countries.

Materials And Methods: A decision-analytic Markov model was developed using IMpassion130 data to evaluate the cost-effectiveness of AnP over a lifetime from the US health care payer and Chinese health care system perspective. Model inputs were derived from IMpassion130 and published literature. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000671DOI Listing

Treatment Timing in Small Cell Lung Cancer, a National Cancer Database Analysis.

Am J Clin Oncol 2020 May;43(5):362-365

Division of Hematology and Medical Oncology, James Graham Brown Cancer Center, University of Louisville.

Objectives: Small cell lung cancer (SCLC) is an aggressive disease treated as soon as possible given its rapid doubling time. Evidence for the appropriate time to chemotherapy initiation (TCI) for SCLC is lacking. This study evaluated TCI in SCLC on a national level. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000676DOI Listing

Twenty-five-Year Follow-up of a Prospective Randomized Trial Comparing Preoperative Versus Postoperative FLAC/Granulocyte Colony-Stimulating Factor Chemotherapy for Stage II Breast Cancer.

Am J Clin Oncol 2020 May;43(5):334-339

Surgery Branch.

Background: Preoperative chemotherapy is important in the management of women with breast cancer, with the ability to downstage the breast primary tumor and axillary lymph nodes. Long-term studies are needed to identify late toxicities, recurrence patterns, and equivalency with postoperative chemotherapy for recurrence-free survival (RFS) and overall survival (OS).

Patients And Methods: We conducted a single-institution prospective randomized control trial comparing preoperative or postoperative fluorouracil, leucovorin calcium, doxorubicin, and cyclophosphamides/granulocyte colony-stimulating factor chemotherapy for women with untreated clinical stage II (T1N1, T2N0, and T2N1) breast cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000667DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7183875PMC

Metabolic Responses to Metformin in Inoperable Early-stage Non-Small Cell Lung Cancer Treated With Stereotactic Radiotherapy: Results of a Randomized Phase II Clinical Trial.

Am J Clin Oncol 2020 Apr;43(4):231-235

Department of Radiation Oncology, Division of Radiation Oncology.

Background: Metformin reduces glucose uptake in physiologic tissues and has been shown to affect non-small cell lung cancer (NSCLC) metabolism. We hypothesized that positron emission tomography (PET) scans could detect the impact of metformin on glucose uptake in NSCLC and we sought to test this hypothesis in a prospective clinical trial.

Materials And Methods: A single-blinded phase II clinical trial was performed with subjects randomized 6:1 to 3 to 4 weeks of metformin versus placebo for inoperable early-stage NSCLC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000632DOI Listing

Current Status of Chimeric Antigen Receptor T-Cell Therapy in Multiple Myeloma.

Am J Clin Oncol 2020 May;43(5):371-377

Department of Hematology and Oncology, William Beaumont Hospital, Oakland University, Royal Oak, MI.

Multiple myeloma (MM) is an incurable malignancy of plasma cells. Recently multiple new therapeutic options have been introduced which was able to improve overall survival but ultimately patient become refractory specifically in patients with poor cytogenetics. Therefore, novel therapeutic options like immunotherapy are needed to improve outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000669DOI Listing

Recent Health Care Expenditure Trends Among Adult Cancer Survivors in United States, 2009-2016.

Am J Clin Oncol 2020 May;43(5):349-355

Miami Cancer Institute, Baptist Health South Florida.

Objective: The objective of this study was to understand recent trends in direct health care expenditures among cancer survivors using novel cost-estimation methods and a nationally representative database.

Materials And Methods: This study was a retrospective analysis of 193,003 adults, ≥18 years of age, using the Medical Expenditure Panel Survey during the years 2009-2016. Manning and Mullahy two-part model was used to calculate adjusted mean and incremental medical expenditures after adjusting for covariates. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000670DOI Listing

Results of the NRG Oncology/RTOG 0848 Adjuvant Chemotherapy Question-Erlotinib+Gemcitabine for Resected Cancer of the Pancreatic Head: A Phase II Randomized Clinical Trial.

Am J Clin Oncol 2020 Mar;43(3):173-179

Memorial Sloan Kettering Cancer, New York.

Purpose: NRG/RTOG 0848 was designed to determine whether adjuvant radiation with fluoropyrimidine sensitization improved survival following gemcitabine-based adjuvant chemotherapy for patients with resected pancreatic head adenocarcinoma. In step 1 of this protocol, patients were randomized to adjuvant gemcitabine versus the combination of gemcitabine and erlotinib. This manuscript reports the final analysis of these step 1 data. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000633DOI Listing

Competing Mortality in Patients With Neuroendocrine Tumors: Erratum.

Authors:

Am J Clin Oncol 2020 02;43(2):146-147

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000664DOI Listing
February 2020

Vincristine Shortage: What Other Options We Have?

Am J Clin Oncol 2020 02;43(2):146-147

Pharmacy Services Department, Cleveland Clinic Abu Dhabi, Abu Dhabi United Arab Emirates.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000648DOI Listing
February 2020

Response Rate and Nonresponse Bias in Oncology Survey Studies.

Am J Clin Oncol 2020 Apr;43(4):229-230

Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, FL.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000665DOI Listing

Systemic Management for Nonmetastatic Castration-resistant Prostate Cancer: A Systematic Review and Network Meta-Analysis.

Am J Clin Oncol 2020 Apr;43(4):288-297

Department of Urology, Cancer Center, Sun Yat-sen University.

Purpose: To indirectly compare the efficacy and safety of systemic therapies used for patients with nonmetastatic castration-resistant prostate cancer (nmCRPC).

Methods: The relevant randomized controlled trials were retrieved from PubMed and the Cochrane Library. Network meta-analyses were used to compare multiple drugs simultaneously for the outcomes of nmCRPC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000660DOI Listing

Cardiac Monitoring for Thoracic Radiation Therapy: Survey of Practice Patterns in the United States.

Am J Clin Oncol 2020 Apr;43(4):249-256

Department of Medicine, Division of Cardiology, Weill Cornell Medical College, New York, NY.

Objective: The American Society of Clinical Oncology (ASCO) 2017 guidelines on cardiac monitoring during cancer treatments identified patients receiving thoracic radiation (TRT) ≥30 Gy (heart in field) at increased risk for developing radiation-induced heart disease (RIHD). ASCO encouraged clinicians to actively screen and monitor for baseline modifiable cardiac risk factors and therapy-induced cardiotoxicity in this high-risk population. Coronary artery calcium (CAC) is an independent risk factor for adverse cardiac events that can be mitigated with preventative medical therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/COC.0000000000000666DOI Listing